Ischemic Dilated Cardiomyopathy (IDCM)

Cardiovascular
1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Vericel
VericelCAMBRIDGE, MA
1 program
1
ixmyelocel-TPhase 21 trial
Active Trials
NCT01670981Completed114Est. Mar 2018

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Vericelixmyelocel-T

Clinical Trials (1)

Total enrollment: 114 patients across 1 trials

NCT01670981Vericelixmyelocel-T

An Efficacy, Safety and Tolerability Study of Ixmyelocel-T Administered Via Transendocardial Catheter-based Injections to Subjects With Heart Failure Due to Ischemic Dilated Cardiomyopathy (IDCM)

Start: Feb 2013Est. completion: Mar 2018114 patients
Phase 2Completed

Related Jobs in Cardiovascular

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space